Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 37
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Cell ; 151(3): 658-70, 2012 Oct 26.
Artículo en Inglés | MEDLINE | ID: mdl-23101632

RESUMEN

Many common diseases have an important inflammatory component mediated in part by macrophages. Here we used a systems genetics strategy to examine the role of common genetic variation in macrophage responses to inflammatory stimuli. We examined genome-wide transcript levels in macrophages from 92 strains of the Hybrid Mouse Diversity Panel. We exposed macrophages to control media, bacterial lipopolysaccharide (LPS), or oxidized phospholipids. We performed association mapping under each condition and identified several thousand expression quantitative trait loci (eQTL), gene-by-environment interactions, and eQTL "hot spots" that specifically control LPS responses. We used siRNA knockdown of candidate genes to validate an eQTL hot spot in chromosome 8 and identified the gene 2310061C15Rik as a regulator of inflammatory responses in macrophages. We have created a public database where the data presented here can be used as a resource for understanding many common inflammatory traits that are modeled in the mouse and for the dissection of regulatory relationships between genes.


Asunto(s)
Interacción Gen-Ambiente , Inflamación/inmunología , Macrófagos/inmunología , Ratones/genética , Sitios de Carácter Cuantitativo , Animales , Células Cultivadas , Técnicas de Silenciamiento del Gen , Lipopolisacáridos/inmunología , Macrófagos/metabolismo , Masculino , Ratones/inmunología , Ratones Endogámicos , Especificidad de la Especie , Organismos Libres de Patógenos Específicos , Biología de Sistemas/métodos
2.
Bioorg Med Chem Lett ; 73: 128882, 2022 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-35817293

RESUMEN

Agonism of the apelin receptor (APJ) has demonstrated beneficial effects in models of heart failure. We have previously disclosed compounds such as 4, which showed good APJ agonist activity but were metabolized to the mono-demethylated, non-interconverting atropisomer metabolites. Herein, we detail the design and optimization of a novel series of N-linked APJ agonists with good potency, metabolic stability, and rat pharmacokinetic profile, which are unable to undergo the same metabolic mono-demethylation cleavage.


Asunto(s)
Piridinas , Receptores Acoplados a Proteínas G , Animales , Apelina , Receptores de Apelina/agonistas , Ratas , Receptores Acoplados a Proteínas G/agonistas
3.
Bioorg Med Chem Lett ; 50: 128325, 2021 10 15.
Artículo en Inglés | MEDLINE | ID: mdl-34403724

RESUMEN

Heart failure (HF) treatment remains a critical unmet medical need. Studies in normal healthy volunteers and HF patients have shown that [Pyr1]apelin-13, the endogenous ligand for the APJ receptor, improves cardiac function. However, the short half-life of [Pyr1]apelin-13 and the need for intravenous administration have limited the therapeutic potential for chronic use. We sought to identify potent, small-molecule APJ agonists with improved pharmaceutical properties to enable oral dosing in clinical studies. In this manuscript, we describe the identification of a series of pyrimidinone sulfones as a structurally differentiated series to the clinical lead (compound 1). Optimization of the sulfone series for potency, metabolic stability and oral bioavailability led to the identification of compound 22, which showed comparable APJ potency to [Pyr1]apelin-13 and exhibited an acceptable pharmacokinetic profile to advance to the acute hemodynamic rat model.


Asunto(s)
Receptores de Apelina/agonistas , Fármacos Cardiovasculares/farmacología , Fármacos Cardiovasculares/farmacocinética , Péptidos y Proteínas de Señalización Intercelular/farmacología , Animales , Área Bajo la Curva , Fármacos Cardiovasculares/síntesis química , Diseño de Fármacos , Semivida , Humanos , Péptidos y Proteínas de Señalización Intercelular/química , Macaca fascicularis , Estructura Molecular , Pirimidinonas/química , Pirimidinonas/farmacología , Ratas , Relación Estructura-Actividad
4.
Am J Hum Genet ; 100(3): 428-443, 2017 Mar 02.
Artículo en Inglés | MEDLINE | ID: mdl-28257690

RESUMEN

Subcutaneous adipose tissue stores excess lipids and maintains energy balance. We performed expression quantitative trait locus (eQTL) analyses by using abdominal subcutaneous adipose tissue of 770 extensively phenotyped participants of the METSIM study. We identified cis-eQTLs for 12,400 genes at a 1% false-discovery rate. Among an approximately 680 known genome-wide association study (GWAS) loci for cardio-metabolic traits, we identified 140 coincident cis-eQTLs at 109 GWAS loci, including 93 eQTLs not previously described. At 49 of these 140 eQTLs, gene expression was nominally associated (p < 0.05) with levels of the GWAS trait. The size of our dataset enabled identification of five loci associated (p < 5 × 10-8) with at least five genes located >5 Mb away. These trans-eQTL signals confirmed and extended the previously reported KLF14-mediated network to 55 target genes, validated the CIITA regulation of class II MHC genes, and identified ZNF800 as a candidate master regulator. Finally, we observed similar expression-clinical trait correlations of genes associated with GWAS loci in both humans and a panel of genetically diverse mice. These results provide candidate genes for further investigation of their potential roles in adipose biology and in regulating cardio-metabolic traits.


Asunto(s)
Enfermedades Cardiovasculares/genética , Regulación de la Expresión Génica , Síndrome Metabólico/genética , Sitios de Carácter Cuantitativo , Grasa Subcutánea/metabolismo , Anciano , Animales , Bases de Datos Genéticas , Perfilación de la Expresión Génica , Estudio de Asociación del Genoma Completo , Técnicas de Genotipaje , Humanos , Masculino , Ratones , Persona de Mediana Edad , Proteínas Nucleares/genética , Proteínas Nucleares/metabolismo , Fenotipo , Reproducibilidad de los Resultados , Transactivadores/genética , Transactivadores/metabolismo
5.
Bioorg Med Chem Lett ; 30(7): 126955, 2020 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-32035698

RESUMEN

This article describes the discovery of aryl hydroxy pyrimidinones and the medicinal chemistry efforts to optimize this chemotype for potent APJ agonism. APJ is a G-protein coupled receptor whose natural agonist peptide, apelin, displays hemodynamic improvement in the cardiac function of heart failure patients. A high throughput screen was undertaken to identify small molecule hits that could be optimized to mimic the apelin in vitro response. A potent and low molecular weight aryl hydroxy pyrimidinone analog 30 was identified through optimization of an HTS hit and medicinal chemistry efforts to improve its properties.


Asunto(s)
Receptores de Apelina/agonistas , Pirimidinonas/farmacología , Descubrimiento de Drogas , Células HEK293 , Ensayos Analíticos de Alto Rendimiento , Humanos , Estructura Molecular , Pirimidinonas/síntesis química , Relación Estructura-Actividad
6.
Anal Biochem ; 568: 41-50, 2019 03 01.
Artículo en Inglés | MEDLINE | ID: mdl-30605634

RESUMEN

Apelin, the endogenous ligand for the APJ receptor, has generated interest due to its beneficial effects on the cardiovascular system. Synthesized as a 77 amino acid preproprotein, apelin is post-translationally cleaved to a series of shorter peptides. Though (Pyr)1apelin-13 represents the major circulating form in plasma, it is highly susceptible to proteolytic degradation and has an extremely short half-life, making it challenging to quantify. Literature reports of apelin levels in rodents have historically been determined with commercial ELISA kits which suffer from a lack of selectivity, recognizing a range of active and inactive isoforms of apelin peptide. (Pyr)1apelin-13 has demonstrated beneficial hemodynamic effects in humans, and we wished to evaluate if similar effects could be measured in pre-clinical models. Despite development of a highly selective LC/MS/MS method, in rodent studies where (Pyr)1apelin-13 was administered exogenously the peptide was not detectable until a detailed stabilization protocol was implemented during blood collection. Further, the inherent high clearance of (Pyr)1apelin-13 required an extended release delivery system to enable chronic dosing. The ability to deliver sustained doses and stabilize (Pyr)1apelin-13 in plasma allowed us to demonstrate for the first time the link between systemic concentration of apelin and its pharmacological effects in animal models.


Asunto(s)
Péptidos y Proteínas de Señalización Intercelular/farmacocinética , Péptidos/análisis , Animales , Cromatografía Liquida , Perros , Ensayo de Inmunoadsorción Enzimática , Hemodinámica , Humanos , Péptidos y Proteínas de Señalización Intercelular/sangre , Péptidos y Proteínas de Señalización Intercelular/metabolismo , Masculino , Ratones , Péptidos/metabolismo , Ratas , Ratas Sprague-Dawley , Espectrometría de Masas en Tándem
7.
PLoS Genet ; 11(12): e1005711, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26694027

RESUMEN

Common forms of atherosclerosis involve multiple genetic and environmental factors. While human genome-wide association studies have identified numerous loci contributing to coronary artery disease and its risk factors, these studies are unable to control environmental factors or examine detailed molecular traits in relevant tissues. We now report a study of natural variations contributing to atherosclerosis and related traits in over 100 inbred strains of mice from the Hybrid Mouse Diversity Panel (HMDP). The mice were made hyperlipidemic by transgenic expression of human apolipoprotein E-Leiden (APOE-Leiden) and human cholesteryl ester transfer protein (CETP). The mice were examined for lesion size and morphology as well as plasma lipid, insulin and glucose levels, and blood cell profiles. A subset of mice was studied for plasma levels of metabolites and cytokines. We also measured global transcript levels in aorta and liver. Finally, the uptake of acetylated LDL by macrophages from HMDP mice was quantitatively examined. Loci contributing to the traits were mapped using association analysis, and relationships among traits were examined using correlation and statistical modeling. A number of conclusions emerged. First, relationships among atherosclerosis and the risk factors in mice resemble those found in humans. Second, a number of trait-loci were identified, including some overlapping with previous human and mouse studies. Third, gene expression data enabled enrichment analysis of pathways contributing to atherosclerosis and prioritization of candidate genes at associated loci in both mice and humans. Fourth, the data provided a number of mechanistic inferences; for example, we detected no association between macrophage uptake of acetylated LDL and atherosclerosis. Fifth, broad sense heritability for atherosclerosis was much larger than narrow sense heritability, indicating an important role for gene-by-gene interactions. Sixth, stepwise linear regression showed that the combined variations in plasma metabolites, including LDL/VLDL-cholesterol, trimethylamine N-oxide (TMAO), arginine, glucose and insulin, account for approximately 30 to 40% of the variation in atherosclerotic lesion area. Overall, our data provide a rich resource for studies of complex interactions underlying atherosclerosis.


Asunto(s)
Aterosclerosis/genética , Proteínas de Transferencia de Ésteres de Colesterol/genética , Endogamia , Sitios de Carácter Cuantitativo , Animales , Aorta/metabolismo , Aorta/patología , Apolipoproteínas E/genética , Apolipoproteínas E/metabolismo , Aterosclerosis/patología , Proteínas de Transferencia de Ésteres de Colesterol/metabolismo , LDL-Colesterol/sangre , Humanos , Insulina/sangre , Macrófagos/metabolismo , Metilaminas/sangre , Ratones , Ratones Endogámicos C57BL , Transcriptoma
8.
Hum Mol Genet ; 22(15): 3023-37, 2013 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-23562819

RESUMEN

The genetics of messenger RNA (mRNA) expression has been extensively studied in humans and other organisms, but little is known about genetic factors contributing to microRNA (miRNA) expression. We examined natural variation of miRNA expression in adipose tissue in a population of 200 men who have been carefully characterized for metabolic syndrome (MetSyn) phenotypes as part of the Metabolic Syndrome in Men (METSIM) study. We genotyped the subjects using high-density single-nucleotide polymorphism microarrays and quantified the mRNA abundance using genome-wide expression arrays and miRNA abundance using next-generation sequencing. We reliably quantified 356 miRNA species that were expressed in human adipose tissue, a limited number of which made up most of the expressed miRNAs. We mapped the miRNA abundance as an expression quantitative trait and determined cis regulation of expression for nine of the miRNAs and of the processing of one miRNA (miR-28). The degree of genetic variation of miRNA expression was substantially less than that of mRNAs. For the majority of the miRNAs, genetic regulation of expression was independent of the expression of mRNA from which the miRNA is transcribed. We also showed that for 108 miRNAs, mapped reads displayed widespread variation from the canonical sequence. We found a total of 24 miRNAs to be significantly associated with MetSyn traits. We suggest a regulatory role for miR-204-5p which was predicted to inhibit acetyl coenzyme A carboxylase ß, a key fatty acid oxidation enzyme that has been shown to play a role in regulating body fat and insulin resistance in adipose tissue.


Asunto(s)
Tejido Adiposo/metabolismo , Regulación de la Expresión Génica , MicroARNs/genética , Carácter Cuantitativo Heredable , Estudios de Asociación Genética , Humanos , Síndrome Metabólico/genética , Síndrome Metabólico/metabolismo , Fenotipo , Polimorfismo de Nucleótido Simple , Sitios de Carácter Cuantitativo , Interferencia de ARN , Procesamiento Postranscripcional del ARN , Transcripción Genética , Transcriptoma
10.
PLoS Genet ; 7(6): e1001393, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21695224

RESUMEN

The relationships between the levels of transcripts and the levels of the proteins they encode have not been examined comprehensively in mammals, although previous work in plants and yeast suggest a surprisingly modest correlation. We have examined this issue using a genetic approach in which natural variations were used to perturb both transcript levels and protein levels among inbred strains of mice. We quantified over 5,000 peptides and over 22,000 transcripts in livers of 97 inbred and recombinant inbred strains and focused on the 7,185 most heritable transcripts and 486 most reliable proteins. The transcript levels were quantified by microarray analysis in three replicates and the proteins were quantified by Liquid Chromatography-Mass Spectrometry using O(18)-reference-based isotope labeling approach. We show that the levels of transcripts and proteins correlate significantly for only about half of the genes tested, with an average correlation of 0.27, and the correlations of transcripts and proteins varied depending on the cellular location and biological function of the gene. We examined technical and biological factors that could contribute to the modest correlation. For example, differential splicing clearly affects the analyses for certain genes; but, based on deep sequencing, this does not substantially contribute to the overall estimate of the correlation. We also employed genome-wide association analyses to map loci controlling both transcript and protein levels. Surprisingly, little overlap was observed between the protein- and transcript-mapped loci. We have typed numerous clinically relevant traits among the strains, including adiposity, lipoprotein levels, and tissue parameters. Using correlation analysis, we found that a low number of clinical trait relationships are preserved between the protein and mRNA gene products and that the majority of such relationships are specific to either the protein levels or transcript levels. Surprisingly, transcript levels were more strongly correlated with clinical traits than protein levels. In light of the widespread use of high-throughput technologies in both clinical and basic research, the results presented have practical as well as basic implications.


Asunto(s)
Perfilación de la Expresión Génica , Variación Genética , Proteoma/análisis , Empalme Alternativo , Animales , Estudio de Asociación del Genoma Completo , Ratones , Proteoma/genética , Proteómica , ARN Mensajero/metabolismo
11.
Am J Hum Genet ; 86(3): 399-410, 2010 Mar 12.
Artículo en Inglés | MEDLINE | ID: mdl-20170901

RESUMEN

Gene by environment (GxE) interactions are clearly important in many human diseases, but they have proven to be difficult to study on a molecular level. We report genetic analysis of thousands of transcript abundance traits in human primary endothelial cell (EC) lines in response to proinflammatory oxidized phospholipids implicated in cardiovascular disease. Of the 59 most regulated transcripts, approximately one-third showed evidence of GxE interactions. The interactions resulted primarily from effects of distal-, trans-acting loci, but a striking example of a local-GxE interaction was also observed for FGD6. Some of the distal interactions were validated by siRNA knockdown experiments, including a locus involved in the regulation of multiple transcripts involved in the ER stress pathway. Our findings add to the understanding of the overall architecture of complex human traits and are consistent with the possibility that GxE interactions are responsible, in part, for the failure of association studies to more fully explain common disease variation.


Asunto(s)
Regulación de la Expresión Génica , Línea Celular , Células Endoteliales/efectos de los fármacos , Células Endoteliales/metabolismo , Ambiente , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Variación Genética , Estudio de Asociación del Genoma Completo , Humanos , Masculino , Modelos Genéticos , Análisis de Secuencia por Matrices de Oligonucleótidos , Fosfatidilcolinas/farmacología , Polimorfismo de Nucleótido Simple , Sitios de Carácter Cuantitativo , ARN Interferente Pequeño/genética , Biología de Sistemas , Transcripción Genética
12.
Genome Res ; 20(2): 281-90, 2010 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20054062

RESUMEN

Systems genetics relies on common genetic variants to elucidate biologic networks contributing to complex disease-related phenotypes. Mice are ideal model organisms for such approaches, but linkage analysis has been only modestly successful due to low mapping resolution. Association analysis in mice has the potential of much better resolution, but it is confounded by population structure and inadequate power to map traits that explain less than 10% of the variance, typical of mouse quantitative trait loci (QTL). We report a novel strategy for association mapping that combines classic inbred strains for mapping resolution and recombinant inbred strains for mapping power. Using a mixed model algorithm to correct for population structure, we validate the approach by mapping over 2500 cis-expression QTL with a resolution an order of magnitude narrower than traditional QTL analysis. We also report the fine mapping of metabolic traits such as plasma lipids. This resource, termed the Hybrid Mouse Diversity Panel, makes possible the integration of multiple data sets and should prove useful for systems-based approaches to complex traits and studies of gene-by-environment interactions.


Asunto(s)
Mapeo Cromosómico/métodos , Estudio de Asociación del Genoma Completo/métodos , Sitios de Carácter Cuantitativo/genética , Algoritmos , Animales , Ligamiento Genético , Lipoproteínas HDL/genética , Masculino , Ratones , Ratones Endogámicos , Fenotipo
13.
Mamm Genome ; 23(9-10): 680-92, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22892838

RESUMEN

We have developed an association-based approach using classical inbred strains of mice in which we correct for population structure, which is very extensive in mice, using an efficient mixed-model algorithm. Our approach includes inbred parental strains as well as recombinant inbred strains in order to capture loci with effect sizes typical of complex traits in mice (in the range of 5% of total trait variance). Over the last few years, we have typed the hybrid mouse diversity panel (HMDP) strains for a variety of clinical traits as well as intermediate phenotypes and have shown that the HMDP has sufficient power to map genes for highly complex traits with resolution that is in most cases less than a megabase. In this essay, we review our experience with the HMDP, describe various ongoing projects, and discuss how the HMDP may fit into the larger picture of common diseases and different approaches.


Asunto(s)
Ratones Endogámicos/genética , Animales , Bases de Datos Genéticas , Ratones
14.
Am J Cardiovasc Drugs ; 22(6): 615-631, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-35570249

RESUMEN

Relatively little is known about the influence of extreme body weight on the pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of drugs used in many disease states. While direct oral anticoagulants (DOACs) have an advantage over warfarin in that they do not require routine drug monitoring, some may regard this convenience as less compelling in obese patients. Some consensus guidelines discourage using DOACs in patients weighing > 120 kg or with a body mass index > 35-40 kg/m2, given a sparsity of available data in this population and the concern that fixed dosing in obese patients might lead to decreased drug exposure and lower efficacy. Per the prescribing information, apixaban does not require dose adjustment in patients weighing above a certain threshold (e.g., ≥ 120 kg). Data from healthy volunteers and patients with nonvalvular atrial fibrillation (NVAF) or venous thromboembolism (VTE) have shown that increased body weight has a modest effect on apixaban's PK. However, the paucity of exposure data in individuals > 120 kg and the lack of guideline consensus on DOAC use in obese patients continue to raise concerns about potential decreased drug exposure at extreme weight. This article is the first to comprehensively review the available PK data in obese individuals without NVAF or VTE, and PK, PD, efficacy, effectiveness, and safety data for apixaban in obese patients with either NVAF or VTE, including subgroup analyses across randomized controlled trials and observational (real-world) studies. These data suggest that obesity does not substantially influence the efficacy, effectiveness, or safety of apixaban in these patients. Trial Registration ARISTOTLE: NCT00412984; AVERROES: NCT00496769; AMPLIFY: NCT00643201; AMPLIFY-EXT: NCT00633893; ADVANCE-1: NCT00371683; ADVANCE-2: NCT00452530; ADVANCE-3: NCT00423319 Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data (MP4 161.22 MB).


Asunto(s)
Fibrilación Atrial , Accidente Cerebrovascular , Tromboembolia Venosa , Humanos , Tromboembolia Venosa/tratamiento farmacológico , Piridonas/efectos adversos , Warfarina/uso terapéutico , Anticoagulantes/uso terapéutico , Fibrilación Atrial/tratamiento farmacológico , Obesidad/complicaciones , Obesidad/tratamiento farmacológico , Accidente Cerebrovascular/epidemiología , Administración Oral , Estudios Observacionales como Asunto
15.
J Immunol ; 182(1): 466-76, 2009 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-19109178

RESUMEN

To understand pathways mediating the inflammatory responses of human aortic endothelial cells to oxidized phospholipids, we previously used a combination of genetics and genomics to model a coexpression network encompassing >1000 genes. CHAC1 (cation transport regulator-like protein 1), a novel gene regulated by ox-PAPC (oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycero-phosphorylcholine), was identified in a co-regulated group of genes enriched for components of the ATF4 (activating transcription factor 4) arm of the unfolded protein response pathway. Herein, we characterize the role of CHAC1 and validate the network model. We first define the activation of CHAC1 mRNA by chemical unfolded protein response-inducers, but not other cell stressors. We then define activation of CHAC1 by the ATF4-ATF3-CHOP (C/EBP homologous protein), and not parallel XBP1 (X box-binding protein 1) or ATF6 pathways, using siRNA and/or overexpression plasmids. To examine the subset of genes downstream of CHAC1, we used expression microarray analysis to identify a list of 227 differentially regulated genes. We validated the activation of TNFRSF6B (tumor necrosis factor receptor superfamily, member 6b), a FASL decoy receptor, in cells treated with CHAC1 small interfering RNA. Finally, we showed that CHAC1 overexpression enhanced apoptosis, while CHAC1 small interfering RNA suppressed apoptosis, as determined by TUNEL, PARP (poly(ADP-ribose) polymerase) cleavage, and AIF (apoptosis-inducing factor) nuclear translocation.


Asunto(s)
Factor de Transcripción Activador 3/química , Factor de Transcripción Activador 4/química , Proteínas Reguladoras de la Apoptosis/química , Pliegue de Proteína , Transducción de Señal/efectos de los fármacos , Transducción de Señal/inmunología , Factor de Transcripción CHOP/química , Proteínas de Transporte Vesicular/química , Factor de Transcripción Activador 3/genética , Factor Inductor de la Apoptosis/fisiología , Proteínas Reguladoras de la Apoptosis/fisiología , Ditiotreitol/farmacología , Perfilación de la Expresión Génica , Células HeLa , Humanos , Análisis de Secuencia por Matrices de Oligonucleótidos , Fosfatidilcolinas/farmacología , Poli(ADP-Ribosa) Polimerasas/fisiología , Factor de Transcripción CHOP/genética , Tunicamicina/farmacología , Proteínas de Transporte Vesicular/biosíntesis , Proteínas de Transporte Vesicular/genética , Proteínas de Transporte Vesicular/fisiología
16.
Circ Heart Fail ; 14(3): e007351, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33663236

RESUMEN

BACKGROUND: New heart failure therapies that safely augment cardiac contractility and output are needed. Previous apelin peptide studies have highlighted the potential for APJ (apelin receptor) agonism to enhance cardiac function in heart failure. However, apelin's short half-life limits its therapeutic utility. Here, we describe the preclinical characterization of a novel, orally bioavailable APJ agonist, BMS-986224. METHODS: BMS-986224 pharmacology was compared with (Pyr1) apelin-13 using radio ligand binding and signaling pathway assays downstream of APJ (cAMP, phosphorylated ERK [extracellular signal-regulated kinase], bioluminescence resonance energy transfer-based G-protein assays, ß-arrestin recruitment, and receptor internalization). Acute effects on cardiac function were studied in anesthetized instrumented rats. Chronic effects of BMS-986224 were assessed echocardiographically in the RHR (renal hypertensive rat) model of cardiac hypertrophy and decreased cardiac output. RESULTS: BMS-986224 was a potent (Kd=0.3 nmol/L) and selective APJ agonist, exhibiting similar receptor binding and signaling profile to (Pyr1) apelin-13. G-protein signaling assays in human embryonic kidney 293 cells and human cardiomyocytes confirmed this and demonstrated a lack of signaling bias relative to (Pyr1) apelin-13. In anesthetized instrumented rats, short-term BMS-986224 infusion increased cardiac output (10%-15%) without affecting heart rate, which was similar to (Pyr1) apelin-13 but differentiated from dobutamine. Subcutaneous and oral BMS-986224 administration in the RHR model increased stroke volume and cardiac output to levels seen in healthy animals but without preventing cardiac hypertrophy and fibrosis, effects differentiated from enalapril. CONCLUSIONS: We identify a novel, potent, and orally bioavailable nonpeptidic APJ agonist that closely recapitulates the signaling properties of (Pyr1) apelin-13. We show that oral APJ agonist administration induces a sustained increase in cardiac output in the cardiac disease setting and exhibits a differentiated profile from the renin-angiotensin system inhibitor enalapril, supporting further clinical evaluation of BMS-986224 in heart failure.


Asunto(s)
Receptores de Apelina/agonistas , Gasto Cardíaco/efectos de los fármacos , Insuficiencia Cardíaca/fisiopatología , Péptidos y Proteínas de Señalización Intercelular/farmacología , Volumen Sistólico/efectos de los fármacos , Animales , Transferencia de Energía por Resonancia de Bioluminiscencia , Células CHO , Cricetulus , Perros , Quinasas MAP Reguladas por Señal Extracelular/efectos de los fármacos , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Células HEK293 , Haplorrinos , Humanos , Técnicas In Vitro , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Fosforilación , Ensayo de Unión Radioligante , Ratas , Tritio , Presión Ventricular/efectos de los fármacos , beta-Arrestinas/efectos de los fármacos , beta-Arrestinas/metabolismo
17.
J Med Chem ; 64(24): 18102-18113, 2021 12 23.
Artículo en Inglés | MEDLINE | ID: mdl-34855405

RESUMEN

This paper describes our continued efforts in the area of small-molecule apelin receptor agonists. Recently disclosed compound 2 showed an acceptable metabolic stability but demonstrated monodemethylation of the dimethoxyphenyl group to generate atropisomer metabolites in vitro. In this article, we extended the structure-activity relationship at the C2 position that led to the identification of potent pyrazole analogues with excellent metabolic stability. Due to the increased polarity at C2, the permeability for these compounds decreased. Further adjustment of the polarity by replacing the N1 2,6-dimethoxyphenyl group with a 2,6-diethylphenyl group and reoptimization for the potency of the C5 pyrroloamides resulted in potent compounds with improved permeability. Compound 21 displayed excellent pharmacokinetic profiles in rat, monkey, and dog models and robust pharmacodynamic efficacy in the rodent heart failure model. Compound 21 also showed an acceptable safety profile in preclinical toxicology studies and was selected as a backup development candidate for the program.


Asunto(s)
Receptores de Apelina/agonistas , Insuficiencia Cardíaca/tratamiento farmacológico , Pirimidinonas/farmacología , Animales , Perros , Descubrimiento de Drogas , Humanos , Pirimidinonas/química , Pirimidinonas/farmacocinética , Pirimidinonas/uso terapéutico , Ratas , Relación Estructura-Actividad
18.
ACS Med Chem Lett ; 12(11): 1766-1772, 2021 Nov 11.
Artículo en Inglés | MEDLINE | ID: mdl-34795866

RESUMEN

The apelin receptor (APJ) is a significant regulator of cardiovascular function and is involved in heart failure and other cardiovascular diseases. (Pyr1)apelin-13 is one of the endogenous agonists of the APJ receptor. Administration of (Pyr1)apelin-13 increases cardiac output in preclinical models and humans. Recently we disclosed clinical lead BMS-986224 (1), a C3 oxadiazole pyridinone APJ receptor agonist with robust pharmacodynamic effects similar to (Pyr1)apelin-13 in an acute rat pressure-volume loop model. Herein we describe the structure-activity relationship of the carboxamides as oxadiazole bioisosteres at C3 of the pyridinone core and C5 of the respective pyrimidinone core. This study led to the identification of structurally differentiated 6-hydroxypyrimidin-4(1H)-one-3-carboxamide 14a with pharmacodynamic effects comparable to those of compound 1.

19.
J Med Chem ; 64(6): 3086-3099, 2021 03 25.
Artículo en Inglés | MEDLINE | ID: mdl-33689340

RESUMEN

Apelin-13 is an endogenous peptidic agonist of the apelin receptor (APJ) receptor with the potential for improving cardiac function in heart failure patients. However, the low plasma stability of apelin-13 necessitates continuous intravenous infusion for therapeutic use. There are several approaches to increase the stability of apelin-13 including attachment of pharmacokinetic enhancing groups, stabilized peptides, and Fc-fusion approaches. We sought a small-molecule APJ receptor agonist approach to target a compound with a pharmacokinetic profile amenable for chronic oral administration. This manuscript describes sequential optimization of the pyrimidinone series, leading to pyridinone 14, with in vitro potency equivalent to the endogenous ligand apelin-13 and with an excellent oral bioavailability and PK profile in multiple preclinical species. Compound 14 exhibited robust pharmacodynamic effects similar to apelin-13 in an acute rat pressure-volume loop model and was advanced as a clinical candidate.


Asunto(s)
Receptores de Apelina/agonistas , Piridonas/química , Piridonas/farmacología , Animales , Receptores de Apelina/metabolismo , Perros , Descubrimiento de Drogas , Haplorrinos , Humanos , Péptidos y Proteínas de Señalización Intercelular/metabolismo , Masculino , Modelos Moleculares , Piridonas/farmacocinética , Ratas , Ratas Sprague-Dawley
20.
Blood ; 112(2): 330-9, 2008 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-18451308

RESUMEN

We have shown previously that oxidized phospholipids (OxPLs), known to accumulate in atherosclerotic vessels, stimulate angiogenesis via induction of autocrine mediators, such as vascular endothelial growth factor (VEGF). We now address the pathways mediating up-regulation of VEGF in human endothelial cells treated with OxPLs. Analysis of structure-function relationship using individual species of OxPLs demonstrated a close relation between induction of VEGF and activation of the unfolded protein response (UPR). Inducers of UPR up-regulated VEGF, whereas inhibition of UPR by chemical chaperones or knock-down of cochaperone HTJ-1 inhibited elevation of VEGF mRNA induced by OxPLs. OxPLs induced protein expression of activating transcription factor-4 (ATF4), an important effector of UPR. Expression levels of VEGF in OxPL-treated cells strongly correlated with induction of the ATF4 target genes ATF3 and TRB3. Knocking down ATF4 was paralleled by loss of VEGF induction by OxPLs. Chromatin immunoprecipitation demonstrated that OxPLs stimulated binding of ATF4 to a regulatory site in the VEGFA gene. Taken together, these data characterize UPR and more specifically its ATF4 branch as an important mechanism mediating up-regulation of VEGF by OxPLs, and allow hypothesizing that the UPR cascade might play a role in pathologic angiogenesis in atherosclerotic plaques.


Asunto(s)
Factor de Transcripción Activador 4/fisiología , Fosfolípidos/fisiología , Desnaturalización Proteica , Transcripción Genética , Factor A de Crecimiento Endotelial Vascular/genética , Células Cultivadas , Endotelio Vascular/citología , Humanos , Oxidación-Reducción , Regulación hacia Arriba
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA